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Abstract
Background: Standard treatment of Duchenne muscular dystrophy (DMD) includes regular physiotherapy. There
are no data to show whether adding aquatic therapy (AT) to land-based exercises helps maintain motor function.
We assessed the feasibility of recruiting and collecting data from boys with DMD in a parallel-group pilot randomised
trial (primary objective), also assessing how intervention and trial procedures work.
Methods: Ambulant boys with DMD aged 7–16 years established on steroids, with North Star Ambulatory
Assessment (NSAA) score ≥8, who were able to complete a 10-m walk test without aids or assistance, were
randomly allocated (1:1) to 6 months of either optimised land-based exercises 4 to 6 days/week, defined by
local community physiotherapists, or the same 4 days/week plus AT 2 days/week. Those unable to commit to a
programme, with >20% variation between NSAA scores 4 weeks apart, or contraindications to AT were excluded.
The main outcome measures included feasibility of recruiting 40 participants in 6 months from six UK centres,
clinical outcomes including NSAA, independent assessment of treatment optimisation, participant/therapist views
on acceptability of intervention and research protocols, value of information (VoI) analysis and cost-impact analysis.
Results: Over 6 months, 348 boys were screened: most lived too far from centres or were enrolled in other trials;
12 (30% of the targets) were randomised to AT (n = 8) or control (n = 4). The mean change in NSAA at 6 months
was −5.5 (SD 7.8) in the control arm and −2.8 (SD 4.1) in the AT arm. Harms included fatigue in two boys, pain in
one. Physiotherapists and parents valued AT but believed it should be delivered in community settings. Randomisation
was unattractive to families, who had already decided that AT was useful and who often preferred to enrol in drug
studies. The AT prescription was considered to be optimised for three boys, with other boys given programmes
that were too extensive and insufficiently focused. Recruitment was insufficient for VoI analysis.
Conclusions: Neither a UK-based RCT of AT nor a twice weekly AT therapy delivered at tertiary centres is feasible.
Our study will help in the optimisation of AT service provision and the design of future research.
Trial registration: ISRCTN41002956
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Background
International guidelines for the multidisciplinary man-
agement of people with Duchenne muscular dystrophy
(DMD) recommend regular physical therapy, including
stretching and positioning regimens 4–6 days/week to
maintain joint ranges, and submaximum aerobic exer-
cise/activity to avoid disuse atrophy. Exercises in water
are highly recommended. They note that the evidence
base for these recommendations is weak and do not de-
tail specific therapy interventions or dosage, nor do they
discuss aquatic therapy [1].
Aquatic therapy (AT), sometimes also called hydro-
therapy, is defined by the UK Aquatic Association of
Chartered Physiotherapists (ATACP) as “a therapy
programme utilising the properties of water, designed by
a suitability qualified physiotherapist specifically for an
individual to improve function, carried out by appropri-
ately trained personnel, ideally in a purpose built, and
suitably heated hydrotherapy pool” [2]. Subsequently,
hydrotherapy was specified to be a programme designed
by a physiotherapist but implemented by carers or teach-
ing assistants, while aquatic physiotherapy is delivered
by a specialist physiotherapist [3]. There are limited
data on the effectiveness of AT in general [4–6], and
none in people with DMD. Our study addressed a 2012
commission from the UK National Institute for Health
Research (NIHR) Health Technology Assessment (HTA)
programme for a feasibility study (HTA 12/144/04).
The specific objective was to collect data that would tell
us whether it was feasible to run a full-scale trial, asses-
sing the clinical effectiveness of AT in maintaining
physical function in people with Duchenne muscular
dystrophy. The principal focus of this paper is the feasi-
bility of a full-scale research study. With the debate
about terminology unresolved [7, 8], we present this
data as an external pilot trial [9], supplemented by a
distillation of qualitative research findings, reported
more fully elsewhere, in line with guidance [10]. Although
some reference to patient and professional views on the
feasibility of the intervention are integral to understand
the feasibility of the trial, this topic is addressed more
fully elsewhere.
Methods
Trial design
The protocol for this pilot trial, which was developed
with patient and public involvement, is available on the
NIHR website [11]. The design was an external pilot
trial for a parallel-group, open-labelled, individually
randomised controlled trial with a 1:1 allocation ratio
incorporating nested qualitative research. This report is
compliant with the Consolidated Standards of Reporting
Trials (CONSORT: see Additional file 1) [12].
Participants
Between October 2014 and June 2015, we planned to re-
cruit 40 boys from six UK centres with a paediatric
neuro-muscular service (Birmingham, Great Ormond
Street Hospital London, Leeds, Oswestry, Southampton,
Sheffield). Medical notes were reviewed to select ambu-
lant boys aged 7–16 years with genetically confirmed
DMD, North Star Ambulatory Assessment (NSAA)
score of ≥ 8, established on corticosteroid therapy, that
is, a patient has been treated with prednisolone or defla-
zacort for at least 6 months with no major change in
drug, dosage or frequency for at least 3 months before
the initial assessment. The major changes were defined
as (1) frequency of change from daily to alternate day or
other non-daily regimen (or vice versa) and (2) dose in-
crease in line with weight is acceptable. The other
change is an exclusion criterion: (3) drug changes from
prednisolone to deflazacort (or vice versa). Potential par-
ticipants were assessed to determine if they were able to
complete a 10-m walk test with no walking aids or assist-
ance as part of the North Star Ambulatory Assessment
(Item 2). We excluded those who were involved in another
clinical trial; had more than 20% variation between screen-
ing and baseline NSAA scores; were unable to commit to
the programme of twice weekly AT for 6 months; and/or
had any absolute contraindications or precautions to AT
listed in the study protocol [11].
Potentially eligible boys and their carers were invited
to an initial consent appointment. After assessment,
written assent from the boys and consent from their
carers, they were randomly allocated in a 1:1 ratio by a
centralised web-based randomisation system provided by
the Sheffield Clinical Trials Research Unit (CTRU) to
AT plus land-based therapy (LBT) or LBT alone. Alloca-
tion concealment was achieved by ensuring the partici-
pant identifier was entered by the physiotherapist,
following which the allocation was revealed; no member
of the study team had access to the randomisation
schedule during recruitment.
Interventions
Standardised AT was prescribed and delivered by an AT-
trained physiotherapist (with specialist knowledge of
DMD), based on the study protocols detailed in a manual,
in 30-min sessions twice weekly in an NHS pool with a
temperature of 34–36 °C (Additional file 2). Standardised
LBT stretches and exercises were prescribed by a specialist
physiotherapist at the baseline appointment, based on the
study protocols detailed in a manual (Additional file 3).
With the aim of reducing missing data, the research
physiotherapists sent reminders to participants who had
not sent back the LBT proforma. A maximum of three
reminder letters were sent to each participant over the
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course of the trial. Those randomised to receive AT were
asked to perform LBT on four of the other 5 days of the
week, while those in the control group were asked to
perform LBT 6 days/week.
Outcomes
The primary outcome was the feasibility of recruitment
of 40 participants within 6 months from six centres.
Additional feasibility outcomes were a decision on the
primary endpoint for a subsequent larger trial; the
number and characteristics of eligible participants who
were approached for the study; the number of partici-
pants randomised, withdrawn, and lost to follow-up;
the number of participants who discontinued AT and
were included and excluded from analysis with reasons;
the recruitment rate; reasons for refused consent; par-
ticipant attrition rates and reasons; data completeness;
feasibility of recruiting participating sites and estima-
tion of the costs; participant views on acceptability of
research procedures and intervention; physiotherapist
views on the intervention/research protocol and per-
ceived contamination of the control group; and inter-
vention optimisation.
The following clinical data were collected for all par-
ticipants: 6-min walk distance (6MWD) [13]; North
Star Ambulatory Assessment (NSAA) [14, 15]; forced
vital capacity (FVC); Child Health Utility 9D Index
(CHU9D)—health state utility [16]; carer quality of life
(CarerQoL—carer burden) questionnaire [17]; activity
limitations measure (ACTIVLIM) [18]; and a health
and social care resource-use questionnaire. Parents were
also requested to return, in stamped addressed envelopes,
diaries recording the LBT stretches/exercises performed
over the previous 4 weeks. In participants allocated to AT,
the Wong-Baker visual analogue scale for pain and the
Children’s OMNI Scale of Perceived Exertion [19] were
assessed before and after each AT session. The therapists
also recorded attendance as well as the AT stretches and
exercises performed.
Blinding
The participants, physiotherapists and physicians were
not blinded to treatment allocation. The statisticians and
health economist were blinded to treatment allocation
until the statistical analysis plan was agreed and signed.
Sample size
The sample size for this external pilot trial was based on
a recommended minimum of 30 participants (15 per
group) for feasibility objectives involving parameter esti-
mation [20]. Assuming a drop-out rate at 6 months of
20%, we set a target of randomising at least 40 partici-
pants (20 per group). While this decision was principally
informed by the need to calculate a sample size for a
full-scale study [9], we believed the recruitment of 40
boys in 6 months might indicate the feasibility of a trial
of n = 100 to 150 in UK centres alone, given a longer re-
cruitment window that would still be acceptable to fund-
ing bodies (1 to 2 years). Initial sample size estimates for
a full-scale study, working in a frequentist framework,
centred around a total n of 610 (80% power, two-sided,
to detect 5%—18 m—difference in the 6MWD with 10%
drop-out at 12 months). We were confident that, by
using Bayesian methods [21] and selecting an meaning-
ful outcome measure with the right measurement prop-
erties, we could reduce this sample size considerably.
Feasibility criterion
This pilot aimed to recruit 40 children in 6 months and
deliver AT to 20 of them. If this objective success cri-
terion was met, then we could deem a full-scale study
potentially feasible. Other feasibility outcomes did not
involve objective stop-go (success) criteria but provided
a basis for improving the research procedures.
Statistical methods
Quantitative analysts (SR and TY) remained blind to
treatment allocation until after the statistical analysis
plan was finalised, the database locked and the data
review completed. The intention to treat population
(ITT) included all patients who were consented and
randomised. This was the primary analysis set, and
unless stated otherwise, all endpoints are summarised
for the ITT population. Depending on the distribution
of the data, continuous variables (e.g., age) were sum-
marised by either the mean and standard deviation or
the median and interquartile range (IQR). AT adher-
ence was assessed by the number and percentage of AT
sessions attended, with mean (SD), median (IQR) and
minimum–maximum numbers. LBT adherence was
measured by the number of days on which the pre-
scribed exercises were performed and the percentage of
the prescribed exercises that were performed on across
the total number of days on which exercise adherence
was recorded.
Descriptive statistics (mean differences between groups
and 95% confidence intervals (CIs)) were derived for
clinical outcomes. Categorical outcomes are presented
as the difference between groups in the percentages in
each category, together with 95% CIs. Available clinical
outcomes at 6 months are presented for the ITT set, by
group and overall. For continuous outcomes, we present
change from baseline by group and overall.
We estimated the cost of the AT intervention to families
and the NHS using information from the quantitative and
qualitative components of the study. Data completeness
was a fidelity outcome of the study. A sensitivity analysis
involving imputation for missing data was not performed.
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Prior to database lock, all missing data was queried
with staff at centres and data management. Question-
naires were scored only when all the items that made
up a domain were complete for each patient and carer
questionnaires.
To further assess the feasibility of a full-scale RCT
evaluating the clinical effectiveness of AT, we proposed
group sequential designs for such a trial that would use
conventional ‘frequentist’ statistics to perform definitive
tests of hypotheses. Testing at the 2.5% one-sided sig-
nificance level, adaptive designs were calibrated to have
80% power to detect a target difference of 9 points in a
primary endpoint of linearised NSAA score at 6 months,
assuming scores are normally distributed with standard
deviation 15 points, values which look realistic given the
results in [22]. Expected and maximum sample sizes of
designs were recorded. Also considered were Bayesian
single-stage designs measuring a primary endpoint of
change from baseline at 6 months in linearised NSAA
score with prior distributions informed by pilot study
data. Properties of Bayesian designs based on pragmatic
sample sizes were computed via simulation, assuming
that on completion the Bayesian trial would declare AT
plus land-based exercises superior to land-based exer-
cises alone if the posterior probability of a benefit of AT
exceeded 0.9.
Intervention optimisation
An independent rater (IR) reviewed patient records
(medical, social and school history), as well as data
from baseline assessments, parent-completed LBT exer-
cise diaries, therapist-completed AT session data and
attendance logs, to determine the levels of treatment
optimisation.
Qualitative research
Trial management group (TMG) meeting minutes and
email communications helped assess barriers to imple-
mentation of the trial and the intervention. Semi-
structured interviews with participants and parents (n =
8 boys) and health professionals (n = 8) were completed
to gather views on acceptability of the AT intervention
and research protocols. All interviews were audio re-
corded and transcribed. Transcripts were coded in
NVivo with analysis completed using a framework ana-
lysis. The methods and results of this qualitative re-
search component will be reported fully in the NIHR
journals library (12/144/04).
Patient and public involvement
Co-authors JP, a young man with DMD, and VW, his
mother and former carer, were involved throughout, in
the design of both the AT intervention and the study, in
the qualitative research analysis and in drafting outputs.
Ethical approval
This trial received ethical approval from Research Ethics
Committee East of England—Cambridge South (14/EE/
0204).
Results
Study implementation
Of the initial six partner centres, two could not partici-
pate (Liverpool, Newcastle), due to a lack of pool avail-
ability or problems accessing excess treatment costs. In
the UK, treatment costs are those that fall upon health-
care commissioners rather than grant-awarding bodies,
where the cost of an experimental treatment exceeds the
cost of the standard care [23]. The other four centres
consented a total of ten boys. In view of this, further 11
UK centres were approached of which two participated
(Southampton and Oswestry), consenting an additional
three boys. The other eight centres did not participate
for the following reasons: inability to obtain regulatory
approval in time, treatment costs, lack of eligible partici-
pants within a reasonable travelling distance, pool avail-
ability and/or lack of staff.
Recruitment and baselines
Recruitment occurred between October 2014 and June
2015, and the participants were to be followed up
26 weeks (±2 weeks) from the date of randomisation.
Overall, 348 boys with DMD were reviewed for potential
eligibility across the six participating sites. Of these, 17
were interested and eligible after an initial telephone
contact, 13 screened and consented, and 12 randomised
to the study: 8 to the AT group and four to the control
group (Fig. 1, Table 1). One withdrew before randomisa-
tion to participate in another clinical trial. The trial
ended when the planned accrual period elapsed.
Numbers analysed, outcomes and estimation
At the 26 week follow-up visit, eight AT and one control
participants contributed 6MWT data (Fig. 2). In the con-
trol group, two participants withdrew before completing
because of the burden of attending the trial procedure for
child and acceptance onto another trial, respectively, while
another was lost to follow-up (Table 2). NSAA data was
available for one of these. Primary and secondary clinical
outcomes showed a small difference favouring AT, but the
numbers are too small to allow significance testing
(Table 3, Figs. 3 and 4). No serious adverse events and 15
adverse events were reported: 10 falls, two influenza
immunisations, and one each for chest infections, sleep
hypo-ventilation and delayed onset muscle soreness. Five
participants recruited to the AT group showed no pain or
fatigue before or after AT on the Wong-Baker and
Children’s OMNI scales while the other three reported
increases in one or both (Table 4).
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Intervention implementation
The median (range) time between randomisation and
initiation of AT was 47 (7–211) days and mean 63 days.
Of the 349 sessions scheduled where data were available,
203 (58.2%) of the expected sessions took place and 146
(41.8%) did not. Cancellation of AT sessions was due to
healthcare provider factors in 47% and participant/family
factors in 43%, with 10% unaccounted for.
Intervention optimsation
AT and LBT adherence summaries are given in Tables 5
and 6, and a summary of AT attendance by participant
Fig. 1 Participant flow diagram
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Table 1 Demographics
Control Intervention Total
Age
n 4 8 12
Mean (SD) 9.8 (2.5) 8.0 (0.9) 8.6 (1.7)
Median (IQR) 9.5 (8.0, 11.5) 8.0 (7.5, 8.0) 8.0 (7.5, 9.5)
Min, max 7, 13 7, 10 7, 13
Ethnicity
English/Welsh/Scottish/Northern Irish/British 3 (75.0%) 2 (25.0%) 5 (41.7%)
Any other White backgrounds 1 (25.0%) 2 (25.0%) 3 (25.0%)
Indian 0 1 (12.5%) 1 (8.3%)
Any other Asian backgrounds 0 2 (25.0%) 2 (16.7%)
Any other mixed/multiple ethnic backgrounds 0 1 (12.5%) 1 (8.3%)
Others (specify)
Korean 0 1 1
Filipino 0 1 1
Polish 1 2 3
Weight (kg)
n 2 5 7
Mean (SD) 25.550 (2.616) 26.480 (4.572) 26.214 (3.910)
Median (IQR) 25.550 (23.700, 27.400) 26.500 (23.800, 26.600) 26.500 (23.700, 27.400)
Min, max 23.70, 27.40 21.70, 33.80 21.70, 33.80
Height (cm)
n 2 5 7
Mean (SD) 117.000 (0.849) 119.960 (6.280) 119.114 (5.339)
Median (IQR) 117.000 (116.400,117.600) 121.000 (114.600,121.200) 117.600 (114.600,121.200)
Min, max 116.40,117.60 113.70,129.30 113.70,129.30
Fig. 2 Number of participants randomised by months
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in Table 7. In general, there was a low return of LBT
forms (n = 4/12) but in those returned, a good adherence
to the prescription.
The independent reviewer (IR) judged the AT pre-
scription as good for three participants, variable by ses-
sion for two and poor for three. For 4/8, they were
realistic and achievable. The number of exercises pre-
scribed per session varied between 4 and 27. Prescrip-
tion compliance varied between 20 and 40% for three
participants and 70 and 90 for five. 5/8 participants
completed additional non-prescribed exercises. The IR
considered exercises not to be appropriately prioritised
in three cases. In part, this resulted from a difference in
understanding regarding whether the AT manual was
to be used as a menu of possible exercises or as a
whole. LBT prescriptions were considered appropriate
and achievable for the four AT participants who
returned the data. However, after intervention by the
community physiotherapist midway through the study,
the number of exercises increased and compliance de-
creased in three. The prescribed number of exercises
ranged from 5 to 13 per day.
Feasibility of the intervention
In five interviews, parents or boys reported some im-
provement was experienced after AT; in one case, the
parent’s view was discordant with that of the boy and
physiotherapist. Less tangible physical benefits, such as
Table 2 External pilot trial completion summary
Site Date initiated Consented Randomised 6-month visit (completed) Withdrew consent Lost to follow-up Other withdrawn
R01 24/10/2014 5 5 4 1 0 0
R02 27/11/2014 2 2 2 0 0 0
R04 11/12/2014 1 1 1 0 0 0
R05 19/11/2014 2 1 1 0 0 1
R06 28/04/2015 1 1 0 1 0 0
R07 29/04/2015 2 2 1 0 1 0
Table 3 Summary of outcomes for primary and secondary outcomes by intervention group
Control Intervention
Outcome measure Follow-up n Mean(SD) Median(IQR) Min–max n Mean(SD) Median(IQR) Min–max
6 min total distance Baseline 4 360(84.98) 362(294.5–425.5) 259–457 8 369.63(78.39) 376.5(313.5–393) 266–525
6 months 1 255 255(255–255) 255–255 8 347.63(81.88) 369.5(288–388.5) 226–463
NSAA score Consent 4 25.75(3.4) 26.5(23.5–28) 21–29 8 23.38(5.93) 22.5(18.5–29) 16–31
Baseline 4 26(4.55) 25.5(23–29) 21–32 8 24.13(5.49) 23.5(19.5–28.5) 18–32
6 months 2 21(15.56) 21(10–32) 10–32 8 21.38(8.47) 21(16–28) 8–33
FVC absolute Consent 4 1.42(0.21) 1.43(1.27–1.57) 1.16–1.66 7 1.52(0.2) 1.5(1.27–1.74) 1.27–1.78
Baseline 2 1.29(0.21) 1.29(1.14–1.43) 1.14–1.43 5 1.34(0.19) 1.39(1.3–1.48) 1.03–1.5
6 months 0 5 1.33(0.42) 1.52(1–1.6) 0.77–1.76
FVC percent Consent 2 90.5(9.19) 90.5(84–97) 84–97 4 97.25(11.62) 97.5(89–105.5) 83–111
Baseline 2 88.5(7.78) 88.5(83–94) 83–94 5 90.8(17.09) 91(79–101) 70–113
6 months 0 5 83.8(22.57) 88(68–93) 56–114
CHU utility value Baseline 3 0.92(0.07) 0.89(0.87–1) 0.87–1 8 0.77(0.23) 0.88(0.59–0.94) 0.39–0.96
6 months 1 0.95 0.95(0.95–0.95) 0.95–0.95 8 0.87(0.09) 0.87(0.82–0.95) 0.71–1
CarerQol score Baseline 3 31.27(10.37) 26.2(24.4–43.2) 24.4–43.2 7 40.6(22.9) 29.3(24.4–59.4) 19.7–81.6
6 months 1 50.1 50.1(50.1–50.1) 50.1–50.1 7 51.27(6.78) 50.1(48.8–50.4) 44–65.8
ACTIVLIM patient score Baseline 3 32.67(9.71) 35(22–41) 22–41 8 30.38(7.58) 32(26.5–34) 17–41
6 months 1 21 21(21–21) 21–21 8 26.88(6.36) 26(22.5–31.5) 19–36
ACTIVLIM patient measure Baseline 3 2.98(2.62) 4.15(−0.02–4.82) −0.02–4.82 8 2.1(1.37) 2.22(1.61–2.78) −0.6–4.15
6 months 1 0.18 0.18(0.18–0.18) 0.18–0.18 8 1.29(1.13) 1.48(0.4–2.1) −0.35–2.73
NSAA is scored from 0 to 34 where higher scores represent higher function. CarerQol is scored from 0 to 100 where higher scores represent better care situation.
CHU values range from 0.33(worst state) to 1 (perfect health). Higher ACTIVLIM scores represent higher activity
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loosening of muscles, were valued by parents and most
physiotherapists, many of whom also noted improvements
in water confidence, social confidence or well-being.
Two boys reported fatigue, one transient pain. Two par-
ents volunteered that they had sustained back injures
through delivering LBT. Parents were highly satisfied
with their aquatic therapists, highlighting their skill in
making exercise fun for boys. It was generally agreed
that the twice weekly AT programme was too burden-
some, with an average journey of 15 miles and competing
Fig. 3 North Star Ambulatory Assessment (NSAA) scores
Fig. 4 Change in 6mWD over 6 months
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pressures on time. Notwithstanding this, there was enthu-
siasm for continuing once weekly hydrotherapy at more
convenient locations, and gaps in attendance (see above)
did not present a pattern that suggested decreased com-
mitment over time.
At two trusts, the physiotherapists challenged the
value of the AT, highlighting that it required diversion
of scarce resources from other activities. While the
training emphasised that AT prescriptions should focus
on the individual’s capability and needs, many thera-
pists thought they had to prescribe stretches suitable
for dry land regardless of relevance. Some were dissatis-
fied with the intervention as a result. NHS reorganisa-
tion, following the Health and Social Care Act 2012,
made it difficult to identify/communicate with commu-
nity AT/physiotherapy services [22] in order to gain the
appropriate NHS R&D permissions, leading us to run
the study and deliver the intervention through specialist
centres. However, all physiotherapists believed that AT
should be delivered in community rather than specialist
settings but valued the new skills they had acquired and
felt that they would advocate regular and intensive AT
where resources allowed. Participating trusts discussed
subcontracting out AT delivery to therapists at centres,
nearer to participant homes (minutes, TMG, 7 July 2014,
19 January 2015). But, with a rare and geographically
dispersed population, we would have had to seek ap-
provals from and contracted with almost as many com-
munity trusts as we recruited participants and would
have had to train as many interventionists.
Over 6 months, the estimated direct NHS costs ranged
from £1970 to £2734 and the societal costs ranged from
£2541 to £3775, based on attendance. Financial pres-
sures and opportunity costs were noted by the physio-
therapists as making the service difficult to justify.
Feasibility of the trial
The physiotherapists and parents believed recruitment
to the trial was difficult because industry trials were
more attractive to parents and co-enrolment is prohib-
ited by UK research ethics committees. They believed
that participant retention was contingent on randomisa-
tion to AT, as confirmed by the drop-out rate observed
in our control arm. Recruitment was particularly difficult
where access to AT was already good.
That was one of the worries that by partaking in
this would it stop him being eligible for another trial
because, as great as this is, as a parent, you’re always
online seeing what NICE are going to approve. (Parent)
I think any patient wanting to, to participate in this
trial would basically have wanted to be in the, err in
the hydro arm or not bother. (Physiotherapist)
The difficulty was there’s so many trials going on
at the moment for Duchenne that it was difficult to
get appropriate patients. And because a lot of ours
get hydrotherapy anyway, yeah, it was difficult.
(Physiotherapist)
Table 6 Intervention adherence: land-based therapy week summary
Randomisation NSAA score Total no. of sessions Total no. of stretches with data/total no. of stretches
prescribed per session (%)
ID Group Consent Baseline 6 months N Median Min Max Mean
R01/005 Research intervention 16 18 17 27 66.67 58.33 100 74.69
R02/001 Research intervention 31 32 33 24 81.87 30.77 100 72.16
R02/002 Research intervention 18 20 17 24 100 87.5 100 97.92
R07/001 Research intervention 19 20 8 20 100 80 100 93.67
Table 5 Intervention adherence: aquatic therapy session summary
NSAA score Total no. of sessions Total no. of stretches competed/total no. of stretches prescribed per session (%)
Randomisation Consent Baseline 6 months N Median Min Max Mean
R01/002 25 27 26 29 33.33 14.81 48.15 30.99
R01/004 31 30 30 29 29.17 12.5 52.17 28.91
R01/005 16 18 17 29 40.91 8.7 68.18 38.63
R02/001 31 32 33 23 92.86 42.86 100 86.77
R02/002 18 20 17 18 93.33 46.67 100 90
R04/001 20 19 15 28 41.21 21.21 100 51.55
R05/001 27 27 25 16 51.67 26.67 63.64 49.76
R07/001 19 20 8 30 100 36.36 100 91.52
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Another major barrier to recruitment was the distance
from the pool. Partly due to therapist availability and
partly due to a national reorganisation of health service
provision and funding at the time, we could not easily
access community pools, with the result being that many
possible participants lived at least 20 miles away with
round-journey times of 2 hours or more. This proved
too great a burden for many families to face twice
weekly for 6 months, especially given that, under the
Department of Health rules for funding research, travel
costs for interventions count as treatment costs and can-
not be reimbursed from a research grant [23].
There were several parents who… couldn’t make that
commitment to twice a week to driving into central
[area name]. There were other parents who said that
if it was more local, if they didn’t have siblings, if they
didn’t feel the child would be tired after school, after
coming all the way into central [area name]…
Generally parents were quite keen on the idea… they
would’ve [participated] had the situation been easier
for them. (Physiotherapist)
Where boys remembered randomisation, they were
negative about it, and only two parents were positive. Some
physiotherapists believed the eligibility criteria should have
been relaxed to allow enrolment of younger or more dis-
abled boys. The physiotherapists and parents found the
completion of intervention documentation for fidelity pur-
poses burdensome, and the physiotherapists would require
more administrative support for any future research. They
believed that a future trial would need long-term follow-up
and mechanistic outcomes in order to identify a treatment
effect. Three families reported the questionnaire battery as
too burdensome, and two complained about the vagueness
of questions on the instruments used to evaluate health-
related quality of life. The 6MWD is typically the most
common primary outcome in trials for ambulant boys with
DMD. As in other studies, concerns about the feasibility of
this assessment were raised during the study, due to
difficulties finding 30-m long corridors and staff trained to
complete the assessment (Minutes, Trial Management
Group, 15 Sep 2014, 03 Nov 2014).
Table 8 provides a data completeness summary; this
shows the number of participants the data were available
for per group and the percentage of data available, with
100% being all data we expected. The NSAA score was
the only outcome available for all participants expected
at each time point, taking into account participant
withdrawals. The questionnaire completion rates are
provided in Table 9 with the ACTIVLIM being the only
questionnaire with missing data in the control group
and the ACTIVLIM and CareQOL having missing data
in the intervention group.
A full-scale RCT following a group sequential design
incorporating up to two interim analyses permitting early
stopping for success or futility according to the ρ-family
error spending criteria (with parameter ρ = 2; see Chapter
7 of [24]) would recruit the following: on average, 74.4 pa-
tients if AT plus land-based exercises are truly superior to
land-based exercises alone; on average, 62.1 patients if
both interventions are equivalent; and a maximum of 93.3
patients. These sample sizes are likely to be prohibitive in
light of the data from this pilot trial. Rather than make
definitive comparisons between interventions, a Bayesian
trial based on a pragmatic sample size would settle for the
less ambitious objective of improving our understanding
of the effectiveness of AT. Assuming a vague uniform (0,
100) prior for the response SD and an independent nor-
mal prior for the treatment difference with mean 5.375
and variance 213.2, Table 10 lists the probability that a
full-scale Bayesian RCT would conclude declaring AT plus
land-based exercises superior to land-based exercises
alone, for various sample sizes and data scenarios. The
prior for the treatment difference is based on pilot study
data: the mean is the difference between the sample mean
changes from baseline in linearised NSAA score on each
trial arm; the prior SD is twice the standard error of the
difference in sample means to down-weight the contribu-
tion of the pilot information.
Table 7 AT attendance summary by participant
Randomisation
number
Actual sessions
attended
Actual sessions
not attended
Patient
factors
Pool
factors
Unknown Available
sessions*
Percent attendance based
on available pool
R01/002 29 16 5 10 1 34 85
R01/004 29 16 4 10 2 33 88
R01/005 30 15 5 10 0 35 86
R02/001 23 29 14 14 1 37 62
R02/002 18 34 20 14 0 38 47
R04/001 28 10 5 5 0 33 85
R05/001 16 12 6 6 0 22 73
R07/001 30 14 8 6 0 38 79
*Due to late-starting, some participants could not have completed 52 sessions by the time of study closure.
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Table 9 Questionnaire completion (%)
Control Intervention Overall
Scoring Follow-up time point Min–max Median Min–max Median Min–max Median
NSAA score Consent 100–100 100 100–100 100 100–100 100
Baseline 100–100 100 100–100 100 100–100 100
6 months 100–100 100 100–100 100 100–100 100
CHU Baseline 100–100 100 100–100 100 100–100 100
6 months 100–100 100 100–100 100 100–100 100
ACTIVLIM Baseline 81.82–100 100 63.64–100 95.45 63.64–100 100
6 months 81.82–81.82 81.82 72.73–100 81.82 72.73–100 81.82
CarerQOL Baseline 100–100 100 85.71–100 100 85.71–100 100
6 months 100–100 100 71.43–100 100 71.43–100 100
Table 8 Data completeness
Scoring Follow-up time point Control (N = 4) n (col %) Intervention (N = 8) n (col %) Overall (N = 12) n (col %)
NSAA score Consent 4 (100) 8 (100) 12 (100)
Baseline 4 (100) 8 (100) 12 (100)
6 months 2 (100) 8 (100) 10 (100)
FVC absolute Consent 4 (100) 7 (88) 11 (92)
Baseline 2 (50) 5 (63) 7 (58)
6 months 0 (0) 5 (63) 5 (56)
FVC % predicted for height Consent 2 (50) 4 (50) 6 (50)
Baseline 2 (50) 5 (63) 7 (58)
6 months 0 (0) 5 (63) 5 (56)
6-min total distance Consent 0 (0) 0 (0) 0 (0)
Baseline 4 (100) 8 (100) 12 (100)
6 months 1 (100) 8 (100) 9 (100)
CHU utility value Consent 0 (0) 0 (0) 0 (0)
Baseline 3 (75) 8 (100) 11 (92)
6 months 1 (100) 8 (100) 9 (100)
CarerQOL score Consent 0 (0) 0 (0) 0 (0)
Baseline 3 (75) 7 (88) 10 (83)
6 months 1 (100) 7 (88) 8 (89)
CarerQOL happy VAS Consent 0 (0) 0 (0) 0 (0)
Baseline 3 (75) 8 (100) 11 (92)
6 months 1 (100) 8 (100) 9 (100)
ACTIVLIM patient score Consent 0 (0) 0 (0) 0 (0)
Baseline 3 (75) 8 (100) 11 (92)
6 months 1 (100) 8 (100) 9 (100)
ACTIVLIM patient measure Consent 0 (0) 0 (0) 0 (0)
Baseline 3 (75) 8 (100) 11 (92)
6 months 1 (100) 8 (100) 9 (100)
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Discussion
This pilot trial has demonstrated that a standard full-
scale randomised controlled trial would not be feasible,
as originally planned, in the UK alone. Our data should
help in planning future studies of both AT and LBT in
DMD. The majority of UK centres we approached could
not participate for a variety of reasons. Variability in pool
availability and AT provision has been highlighted as a
problem by a national charity [25]. NHS treatment costs
(see the “Results” section) have long been known as a
barrier to the timely completion of publicly funded re-
search in the UK, and our study also suffered as a result of
the lack of nationally implementable guidelines [26, 27].
In the participating centres, which included some of
the largest in the UK, the majority of boys assessed did
not meet our eligibility criteria (Fig. 1). In those who
were ambulant and therefore eligible, many did not par-
ticipate, mostly because of current or anticipated partici-
pation in other trials. In the time between planning our
study and implementing it, several trials started, the ex-
istence of which we had not been aware. Although the
protocols of some, such as the DMD Heart Protection
Study (ISRCTN50395346), permitted co-enrollment, we
were unable to obtain ethics committee approval for co-
enrollment to our own study.
All those randomised to the AT group completed the
study, but three of the four in the control group did not,
for the same reasons that prevented initial recruitment,
as discussed above. Randomising as individuals meant
that one family with more than one eligible boy had two
boys in the AT group and another in the control group.
Our study was not powered to detect clinically important
differences when AT was added to LBT. The intended
sample of 40 would have permitted power calculations for
a future full-scale trial [20, 28]. There have not been any
previous reported studies of AT in DMD. Due to problems
associated with the 6MWD, the routinely collected NSAA
[15, 29, 30] appears to be the most feasible outcome for
any future full-scale trials. This could minimise data collec-
tion costs and loss of information due to the NSAA being
routinely collected for DMD patients at clinic appoint-
ments. Rare disease groups can benefit from the use of
the cohort multiple randomised controlled trial design
(cmRCT) or Trials Within Cohorts (TWiCs) [31], which
uses staged-informed consent to overcome drop-out and
other problems associated with interventions in the ab-
sence of equipoise [32]. Pragmatic trials of physiotherapy
interventions in DMD could be more feasible if the disease
registries such as the NorthStar Project were able to adopt
cmRCT/TWiCs functions in the future.
When planning this study, we found that there were
no agreed validated standardised protocols for either
AT or LBT, either in terms of what to do or the dosage
(frequency and duration). We therefore created our
own manuals for both (reported separately). Conven-
tionally, in the UK, AT is given as 6-week blocks but
we chose a higher dosage to ensure that any benefit
would not be missed through under-dosage. Independent
review of the intervention optimisation showed that the
dose varied and that the protocols were not always ap-
propriately applied. In general, AT was well tolerated
but in some, it caused pain or fatigue.
For LBT, there was some evidence of an inverse rela-
tionship between dosage and compliance. In addition,
the poor return of LBT data suggests poor compliance.
One mother of a family with four affected boys told us
she never performed home LBT as she did not have the
time or resources.
We have insufficient evidence to demonstrate whether
AT provides value for money in terms of quality-adjusted
life years gained. The direct (health system) costs (£1970 to
£2734) are less than haemodialysis for children aged over
6 months (£10,296 to £46,352 for three sessions per week)
or specialist paediatric services for cystic fibrosis (£2554 to
£24,809 over 6 months) [33]. Based on experience accrued
before and since the trial was designed, service users and
therapists have proposed a number of ways that services
could be made cheaper and more feasible.
1. Health systems could increase the number of pool
sessions offered by the health system by combining
access to children with other neuromuscular conditions
in the pool and requiring parents to be in the pool
while a physiotherapist rotates between clients.
Table 10 Results are based on 10,000 simulations
True treatment
difference
Probability future RCT declares AT plus optimised land-based exercises superior to optimised land-based exercises alone
N = 20 N = 30 N = 40 N = 60
0 0.10 0.10 0.11 0.10
δ/2 0.27 0.33 0.38 0.39
δ 0.52 0.64 0.73 0.75
3δ/2 0.75 0.88 0.94 0.93
N is the total sample size divided equally between interventions. Primary endpoint of a future Bayesian trial would be change from baseline at 6 months in
linearised NSAA score, and the ‘true treatment effect’ refers to the underlying difference between average outcomes on each intervention. Future trial data
are simulated according to the model θ^ ~ N(θ, 4σ2/N) and s2 ~ (σ2/N) χN
2
− 2 setting σ = 15 and δ = 9, where θ^ is the difference between sample mean outcomes
on each treatment arm (and θ is the true treatment difference) and s2 is the pooled sample response variance
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2. Health systems should enable parents to safely deliver
targeted AT techniques, through in-pool training and
diagram sheets. Give them responsibility to access
warm water pools between courses provided by the
health system.
3. Health systems and voluntary sector organisations
could enable parents to link with each other, in
order to share the documented high costs of warm-
water pool hire and conduct AT exercises regularly
at their convenience [25]. In some places, this
‘hydrotherapy club’ model has been enhanced by
limited support from qualified and volunteer student
physiotherapists, without being cost-prohibitive [34].
4. For boys who are in special schools, access is already
often better where technical instructors, physical
therapy assistants and other staff members can
deliver AT based on our manuals with limited
oversight by health system physiotherapists.
Both the qualitative research findings and the patient
and public involvement underline how much families
value AT in participation terms and dedicated parents are
willing to negotiate complex systems in search of better
access. We end this discussion section with a statement
from our service user representatives, James and Victoria:
The ideal is open-ended, weekly therapist-led AT, but
the current service is sporadic four- to six-week blocks.
James found he had to rebuild all his confidence when
coming back to therapist-led AT after breaks in service.
Sustaining water confidence and self-esteem is very
important to self-management. If you have a big break
then, each time you go back, the likelihood is you’ve
physically deteriorated – so the break just highlights
the physical deterioration. It’s easier, psychologically,
to experience gradual increasing difficulties over time,
rather than perceive step changes in the decline of
physical function. The problem then is, how do we do
approach the ideal?
Conclusions
Our study has shown that a full-scale RCT of AT, designed
along frequentist lines, is not feasible in the UK alone.
Any future studies should consider Bayesian approaches
to achieve a statistically valid result with an achievable
number of patients in a reasonable timeframe. Even then,
the effect on motor function may not be very marked and
a composite assessment also capturing individual patients
well-being should be considered. We have demonstrated
that AT has other benefits which are valued by people with
DMD and physiotherapists. Two reviews and a conceptual
framework [35, 36] offer guidance for selecting measures
of participation which, we propose, should be considered
as primary outcomes in future research.
Our study highlights, once again [37], the lack of basic
information on the effectiveness, selection/prioritisation,
dosage, and practicability of valid therapy protocols for
stretches/exercises in people with DMD. Our treatment
manuals offer a basis for a service, but more work is
needed to understand how it can best be made persona-
lised [38–41], developmentally appropriate [42] and co-
ordinated. To ensure new models of provision meet the
needs of stakeholders, further service development of
the work should be co-produced [39, 43, 44], involving
DMD family members, specialist and community phys-
iotherapists, representatives of schools and/or teaching
assistants, community AT pool providers and third sec-
tor organisations. Participation is currently inequitable,
being determined by income and location [25, 45]. The
UN Convention on the Rights of Persons with Disabil-
ities (Articles 19, 25 and 30) [46] and, in the UK, The
Children and Families Act 2014 (special educational
and health provision reasonably required) [47, 48] pro-
vide an ethical and legal basis to guide co-production
of new services. Where the capacity of parents and
teaching assistants allows [49], physiotherapists can
build capacity and share responsibility for the work of
rehabilitation in the child, family and community. This
could involve providing training and printed information
on exercises that can be performed safely and effect-
ively with their boys, as well as improved signposting to
services [50–55].
Any future studies should consider alternative strat-
egies such as Bayesian analytical approaches to deliver a
statistically valid result with an achievable number of pa-
tients in a reasonable timeframe. To improve participa-
tion by NHS trusts in future trials, we recommend a
review of excess treatment cost provision, early engage-
ment of NHS England, consideration of refunding travel
costs to study participants and randomisation by family
and not individual.
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